A Closer Look at Performance Enhancing Drugs in Sports
By: Jesse Donathan
“He tested positive again!” Those were the words I was greeted with upon logging on to twitter Sunday, December 23 and seeing the first message of the day from UFC two division champion Daniel Cormier. Unfortunately, Cormier didn’t even need to elaborate any further. Those four short words said it all. Subconsciously, we all knew who Daniel was talking about without needing any further explanation. He of course was talking about Jon “Bones” Jones. Widely considered the best fighter in the sport, according to a December 23, 2018 Jack Crosby article from cbssports.com titled, “UFC 232 moved to Los Angeles after Jon Jones drug test includes miniscule amount of banned substance” Jones has tested positive for performance enhancing drugs once again though he has not been suspended and his title fight against Alexander Gustafsson remains as previously scheduled.
An abnormality in a pre-fight drug test taken by former UFC light heavyweight champion Jon Jones has forced UFC to move Saturday’s UFC 232 pay-per-view from Las Vegas to just outside of Los Angeles. Jones’s drug test showed a trace amount of Turinabol, the banned substance that saw him suspended 15 months by the United States Anti-Doping Agency, remained in his system. The USADA referred to it as “an extremely low level,” concluding that it is a residual amount “from his prior exposure for which he was previously sanctioned.
In an espn.com article from Brett Okamato, “Jon Jones subject to drug testing from USADA, VADA” published on December 24, 2018 Okamato reports that as a result of the “atypical” anti-doping test results Jones will be enrolling into VADA testing, testing Jones had initially elected not to participate in, drawing widespread criticism before this latest flagged test result. Okamato would go on to write:
Jon Jones, as of Monday afternoon, is subject to drug testing from both the United States Anti-Doping Agency (USADA) and the Voluntary Anti-Doping Association (VADA).
According to California State Athletic Commission executive director Andy Foster, Jones, 31, enrolled in the VADA program on Monday. As a UFC athlete, he is still enrolled in the promotion’s mandatory USADA program as well, making him the first MMA fighter to be enrolled to both programs at the same time.
Jones is no stranger to banned substances, as described above this latest positive test for miniscule amounts of Turinabol are alleged to be trace deposits from the last positive test which Jones failed over a year ago. According to a September 13, 2017 article, “Jon Jones’ B sample confirms failed drug test from UFC 214” written by the BBC, “USADA confirmed that Jones had tested positive for an anabolic steroid called Turinabol, just one day before he defeated Daniel Cormier in Anaheim to reclaim the UFC’s light-heavyweight title.
Jones has denied knowingly taking the banned substance, and requested the test of his B sample, but this has now confirmed presence of Turinabol.” This latest December 2018 “atypical” result is alleged to be from this previous 2017 offense. Mixed martial arts journalist Dave Meltzer of The Wresting Observer isn’t so sure, stating via twitter social media on December 24, 2018 that, “when the same expert says a substance can only be detected for 6 weeks in 2017 and then tells you it was detected 17 months later in 2018, that tells me the “expert” may be smart, but also may be a con.”
Originally reported by Aaron Bronsteter, UFC content editor for The Sports News (TSN) via twitter, Jones tested at 60 picograms per milliliter on December 9, 2018. Interestingly enough, according to Bronsteter Jones originally tested positive back in 2017 for the same banned substance of between 20-80 picograms per milliliter. In other words, Jones’s most recent “atypical” flagged test is within the same range of his 2017 failed urinalysis for which he was originally sanctioned. Yet, Jones’s fight with Gustaffson remains as previously scheduled despite the NSAC’s refusal to license Jones. Rather questionably, the California State Athletic Commission is signing off on this fight when the Nevada State Athletic Commission would not, as the UFC bends over backwards to make sure the fight continues as scheduled.
According to a NCBI.gov article titled, “The pharmacokinetics of Oral-Turinabol in humans” originally published in September of 1991 by Schumann, W. oral-Turinabol has a terminal half-life of 16 hours. For those who may not be familiar with the term half-life, it is defined by Merriam-Webster’s dictionary as, “the time required for half the amount of a substance (such as a drug, radioactive tracer, or pesticide) in or introduced into a living system or ecosystem to be eliminated or disintegrated by natural processes.” Note, it’s been over a year since Jones’s original positive test.
In a July 7, 2016 Associated Press report at the nydailynews titled, “Tearful Jon Jones denies taking PEDs after positive test blows up UFC 200’s main event” Jones was reportedly adamant that, “he (had) no idea why his June 16 test would yield a violation after he passed seven other doping tests this year.” It was later revealed that Jones had tested positive for the anti-estrogen blocker clomiphene and the aromatase inhibitor Letrozole according to Marc Raimondi of mmafighting.com in his July 23, 2016 article titled, “Brock Lesnar tested positive for anti-estrogen; Lesnar, Jon Jones won’t face UFC fine.”
In a January 8, 2015 Ariel Helwani article for mmafighting.com, “Nevada Athletic Commission head: Jon Jones’ testosterone clean prior to UFC 182; carbon isotope ratio test conducted” we find some invaluable information in understanding the parallel world of doping in combat sports. In explaining testosterone to the reader, Helwani heads to WebMD to define testosterone as “the “male” hormone accounting for strength and endurance.” The WebMD definition goes on to state “for every molecule of testosterone produced by the body, another molecule of a substance called epitestosterone, which does not enhance performance, is made.” In examining some of the criteria set forth by regulatory bodies in mixed martial arts, the Helwani article would go on to explain that:
In a normal male body, the ratio of testosterone to epitestosterone, the T/E ratio, is about 1:1. But variation can occur in individuals, and the World Anti-Doping Code has deemed 4:1 as the threshold for a positive test.”
Note: Nevada’s threshold is 6:1.
This is some information worth sitting on and examining closer, because these ratios are incredible in comparison to the data we previously broke down barney style. Though I admittedly only had a C average when I graduated with a Bro-Science degree in English, the fact “the World Anti-Doping Code has deemed 4:1 as the threshold for a positive test,” seems to me to be a piece of information too incredible to skip over. There is nothing to see here people… move along!
If 1:1 is our baseline for normal, athletes could potentially have a 3:1 ratio of testosterone molecules made to every molecule of epitestosterone and still be well within the acceptable range of the World Anti-Doping Code and therefor passing the test with flying colors. That is literally three times what is considered normal and the scary part is that only a 4:1 ratio is considered a positive test. Understanding this information alone puts the performance enhancing drug question in combat sports in an entirely different light. If you are normal male athlete with a 1:1 T/E ratio you may think twice about stepping in there with another normal athlete who has a T/E ratio of 3:1 or even greater. Suddenly, the question of performance enhancing drugs in sports moves from the lens and perspective of cheating to an entirely new premise of leveling out the playing field.
According to Dr. Johnny Benjamin of mmajunkie.com, a noted medical combat-sports specialist, in his April 5, 2012 article titled, “Medical Beat: What are T:E ratios? And why do cut off limits vary?” ethnicity and other variables can play a role in T:E ratios.
Most men have a ratio of T to E of 1:1, which means normal men have equal amounts of T and E in their blood. There is some normal ethnic and time of day variation in the normal T/E ratio (as low as 0.7:1 and as high as 1.3:1).
Statistics reveal that a ratio of up to 3.7:1 will capture 95 percent of all normal men, and a ratio of up to 5:1 will capture greater than 99 percent of all men. That’s why the World Anti-Doping Agency (WADA) allows up to 4:1 (so its test is at least 95 percent accurate) and the Nevada State Athletic Commission, the NCAA and some others allow up to 6:1 (for 99 percent accuracy).
Flashing back to Helwani’s January 2015 article, he would go on write about Jon Jones’s flagged urinalysis sample:
So on Dec. 4, Jones’ T/E ratios came up as .29 and .35. Jones actually took two drug tests that day because, according to Nevada Athletic Commission executive director Bob Bennett, his first urine sample was “watery.” On Dec. 18, his T/E ratio came up as .19. Clearly, all three ratios were below that of the average male.
When our baseline is a 1:1 ratio, punching that information into the calculator still returns a result of one when you attempt to divide 1 by itself. Notice where Jon Jones’s decimal point is, we aren’t talking about 2.9 here. We are talking about 0.29, followed by 0.35 and incredibly on December 18 he tested out at 0.19. Jones was on his way to ruling the women’s UFC light heavyweight division until his dying day with those kinds of results. Helwani later writes, “by contrast, Daniel Cormier, Jones’ opponent at UFC 182, had a T/E ratio of .4 on Dec. 2 and .48 on Dec. 17. Cormier passed both those tests.” Even Daniel Cormier’s numbers are well below the 1:1 ratio considered as the baseline for normal testosterone to epitestosterone molecule production according to the WebMD synopsis originally provided by Helwani. While Jones’s test was the more suspicious between the two, there is no question Cormier is testing well below the normal threshold by regulatory body standards.
The World Anti-Doping code provides leeway up to a 4:1 ratio, the Nevada State Athletic Commission 6:1 according to Helwani and both Jones and Cormier are testing out with their decimal points on the wrong side of the calculations. Instead of testing for a high testosterone to low ratio epitestosterone, their decimal points are on the wrong side of the dotted line. In my opinion, both athletes have curiously low T/E ratios, however with Jones being the more questionable between the two he seemed to get the vast majority of negative publicity surrounding the testing results. In a seemingly real-life Jedi Mind trick, Nevada State Athletic Commission executive director Bob Bennet was quoted by Helwani as stating that, “there’s no problem with Daniel, trust me.”
Putting things into perspective here, according to an April 5, 2012 article by Jesse Holland of mmamania.com titled, “Report: Alistair Overeem T/E ratio comes back a whopping 14:1 following failed drug test” manipulating an athlete’s testosterone to epitestosterone ratio is a known performance enhancement technique in competitive sports and one which is exploited by athletes in combat sports.
Ultimate Fighting Championship (UFC) Heavyweight number one contender Alistair Overeem, who flunked a surprise drug test in advance of his UFC 146 title fight opposite Junior dos Santos on May 26 in Las Vegas, has returned a staggering testosterone-to-epitestosterone (T/E) ratio of 14:1 in his failed urine test, according to Nevada State Athletic Commission (NSAC) Executive Director Keith Kizer.
Holland would go to write, “by comparison, Chael Sonnen’s T/E ratio following his failed urine test in the wake of his middleweight title fight in the UFC 117 main event back in October 2010, was 16.9:1.” Let that sink in for a second, 16.9 molecules of testosterone per one molecule of epitestosterone. In a universe where 1:1 is considered the baseline normal ratio, that’s simply unfathomable. Those are the kinds of numbers that would make Lance Armstrong blush. And according to Nevada State Athletic Director Bob Bennett Daniel Cormier competing at .40:1 and .48:1 isn’t a problem? “These are not the droids you’re looking for,” echo’s Obi Wan Kenobi in a galaxy, far, far away.
Yet, Jon Jones’s .29:1 and .35:1 ratio is a problem? With a third test ordered for Jon Jones and Jones only on December 18th with an astonishingly low .19:1 T/E ratio result obviously raising red flags on top of red flags. These are the T/E ratios I would expect from an adolescent child, yet they are the results of performance enhancing drug tests for two of the world’s leading mixed martial arts champions?
Astonishingly, in a July 1997 report by Werner W. Franke and Brigette Berondonk, “Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government” published at Clinical Chemistry we find a wonderfully insightful and behind the scenes look at the world of pharmaceutical based athletic performance enhancing drug use. Describing the East German Democratic Republics (GDR) state sponsored doping program, Franke and Berondonk wrote of one of the GDR symposium’s goals to evade increased scrutiny by the International Olympic Committee (IOC) by administering, “testosterone as well as dihydrotestosterone by nasal spray, especially in those events in which the psychotropic effects of testosterone, such as increased aggressiveness, are considered important, as well as to evade the doping tests.”
In a fascinating and insightful look at the corruption within the regulatory bodies, Werner and Berondonk describe how situations deemed embarrassing or too damaging for some nations, regulatory bodies, promotions or athletes were simply covered up.
Finally, however, even when an athlete of the GDR, or another socialist country, was tested at a risky moment, i.e., when her or his urine was expected to still contain metabolites of synthetic steroids or an above-normal T:E ratio, there was no reason to panic. From the written records, it appears that, usually, one of the members of the international doping control committee was able to clear away the sample. For example, the Stasi reports from Höppner, who served many years on control committees, describe when and how he covered up certain drug-positive cases and arranged falsely negative findings, often after consultation with a ZK member; if worst came to worst, he acted directly by carrying out a urine exchange.
It’s unreal that Jon Jones has tested positive, again, yet reportedly for residual amounts from a previously failed test which he has already been sanctioned for. Contributing to the madness is the fact Jones is reportedly unable to be sanctioned by the Nevada State Athletic Commission, so the UFC has moved the entire show to just outside Los Angeles, California where Jones can be sanctioned by the California State Athletic Commission. The logistics involved for this kind of move, the money lost, and tremendous burden put on nearly everyone who had planned on attending the event in Las Vegas, with flights and hotels booked etc. is simply mind blowing.
There is plenty of blame to go around here. While Jones is the obvious target, how is it just days before the fight with Gustafsson this trace amount of Turinabol was only now discovered? If anything, this latest embarrassment for Jones only shines the light on the ineptitude of regulatory bodies and their administrative policies which ultimately lead to public relations nightmares just like this latest positive test by Jones for a performance enhancing drug he had been previously sanctioned on over a year ago now. Its time for additional oversight and reform in the combat sports entertainment industry.
Alvarez-Golovkin And The Drug Testing Story That Never Should Have Been
By Jake Donovan
Saul ‘Canelo’ Alvarez and Gennady Golovkin have developed one of the most contentious rivalries in the sport today—so much, that even random social media discussion has somehow become headline news.
The latest twist involving the best two middleweights in the world today once again revisits the drug testing subplot, with the validity of random testing provided somehow—and falsely—called into question.
Both boxers were subject to random drug testing as administered by Voluntary Anti-Doping Agency (VADA)—a Las Vegas-based company founded by Dr. Margaret Goodman, a longtime advocate for the safety and health of boxers—surrounding their rematch this past September in Las Vegas.
The same agency was involved in their first fight one year prior, with testing at the time serving as merely a footnote. The far greater focus was on their HBO Pay-Per-View headliner ending in a highly questionable split decision draw which many felt Golovkin deserved to win.
The two camps came to terms for an agreed-upon rematch, which was due to take place this past May. However, the drug testing angle became the major focal point after Alvarez was discovered to have failed two VADA-conducted tests, both showing trace amounts of the banned substance Clenbuterol.
Even while armed with the alibi of the substance being unknowingly digested through contaminated meat—an ongoing epidemic in Alvarez’ native Mexico—the ultimate decision rendered down by the Nevada State Athletic Commission was for the superstar athlete to serve a six-month suspension, while also issuing the reminder that all athletes are responsible for what goes into their bodies regardless of means of consumption.
Alvarez took the punishment, also agreeing to enroll in year-round VADA testing which began in May. The decision served as the first step toward rescheduling his rematch with Golovkin, with the two sides going beyond their internally-imposed deadline in ultimately coming to terms to once again meet in September.
With Alvarez already enrolled, VADA agreed to create a specific testing program for the rematch, with the September 15 fight night date serving as the closing period. Alvarez won a majority decision in a fight where most ringside observers felt a draw or a close Golovkin victory was the more appropriate call, but the outcome not as contentious as was the case one year prior.
Except to the Golovkin camp.
The loss ended his reign of 20 successful defenses (which includes five defenses of an “interim” title, which some historians dismiss), tying him with Bernard Hopkins, a stakeholder in Golden Boy Promotions, Alvarez’s promoter. The post-fight drug test which followed was also supposed to end the testing period as it pertained to this bout, although Alvarez was due to remain in the program as per his contracted agreement to year-round testing which runs through May 2019.
This somehow became a topic of discussion two months after the fact.
A random discussion on social media called to question whether or not Alvarez remained enrolled in VADA’s program without interruption. The inquiry came about after the agency welcomed to the program reigning secondary super middleweight titlist Rocky Fielding, who will face Alvarez on December 15 at Madison Square Garden in New York City.
The conversation took a bizarre turn when Tom Loeffler—managing director of 360 Promotions and the driving force behind Golovkin’s career—offered a response suggesting that post-fight testing was yet another angle in the rivalry in which their side was dealt the short straw.
“VADA scheduled a random test for GGG a week after the fight,” Loeffler stated on social media. “I made sure that Canelo was also going to be tested. Next day the random test was cancelled. Strange that it was scheduled then cancelled, maybe Canelo was already in [Mexico] eating steaks celebrating his ‘decision’.”
Not only was it the wrong setting for such a pointed remark but was entirely incorrect in its implication.
The eventually canceled test was initially scheduled by the Nevada State Athletic Commission, which has often contracted VADA for testing needs. However, the decision to test both fighters that far after the fight was not made by VADA, as Golovkin’s specific obligation to the program ended on fight night.
“Tom Loeffler’s tweets regarding Golovkin/Alvarez testing are not correct,” Goodman told BoxingInsider.com via email in response to the conversation. “VADA tested both fighters many times leading up to their rematch and post-fight. Mr. Alvarez remains in VADA’s year-round testing program and subject to testing.
“Golovkin’s program ended September 15, 2018. The commission initially requested that we arrange to test both fighters again. Since many fighters travel after an event, and as Golovkin was no longer in VADA we confirmed his whereabouts. However, soon after the confirmation, the commission changed their decision.”
The decision as well as Goodman’s take were both subsequently confirmed by Golovkin’s side while offering its best efforts to walk back such comments.
“It was not VADA that cancelled the test, apparently it was the Commission,” Loeffler confirmed to BoxingInsider.com via text. “I didn’t mean to disparage VADA in any way; I’m a firm believer in what they do and that they are the best testing we have to try to prevent any banned substance use. Their testing is what showed the two positive tests for Canelo for Clenbuterol and that wouldn’t have shown up had we not started early testing with VADA.
“They cancelled the test for GGG, not sure what they did with Canelo, I just figured both were cancelled, but that information would have to come from VADA or the commission. We have insisted on VADA testing for all of the GGG fights as well as (former World heavyweight champion Wladimir) Klitschko fights in Europe and Moscow, so we believe in their testing program being effective and complimenting the WBC clean boxing program.”
Golovkin remains on the hunt for a new platform to carry his next fight and beyond. The knockout artist from Kazakhstan was among the many boxers left without a network home after HBO—the premium cable giant whom has aired all but two of his bouts since his stateside debut in 2012—announced in September that it would no longer remain in the boxing business following their final forthcoming December 8 telecast (fittingly, presented by Loeffler’s 360 Promotions). Talks are ongoing with many top players, including the top brass at ESPN, Showtime and sports streaming service DAZN, the latter with whom Alvarez signed a record-breaking contract and on which he will debut in December.
There stands a chance that their paths will once again cross. Hopefully by then, the storylines will remain limited to their in-ring rivalry and not news items that never should have been news to begin with.
Wilder vs. Fury Drug Testing Status
By: Jake Donovan
While the promotion is in full bloom for the forthcoming December 1 heavyweight title clash between Deontay Wilder and Tyson Fury, the seeds for random drug testing protocol haven’t even been planted.
The clash of heavyweight titans—which will air live via Showtime Pay-Per-View from the Staples Center in Los Angeles, Calif.—has been at least seven weeks in the works, but those involved in the promotion have yet to file the necessary paperwork with Voluntary Anti-Doping Agency (VADA). The Nevada-based organization oversees all drug testing as part of the World Boxing Council’s (WBC) Clean Boxing Program, in which enrollment for all WBC-ranked boxers is supposed to be the standard.
“As of (Saturday), VADA has not received paperwork on Mr. Tyson Fury’s enrollment in the WBC’s CBP,” Dr. Margaret Goodman, founder and president of VADA told BoxingInsider.com over the weekend.
BoxingInsider.com contacted the WBC in mid-September on the subject when first learning of the development, but the inquiry was apparently lost in the shuffle as the Mexico-based sanctioning body was preparing for its annual convention which was held last week in Kiev, Ukraine.
Several topics were addressed during the convention, including a fresh batch of mandatory title fights and eliminators ordered which managed to generate the most headlines regarding anything WBC-related.
Not quite as pronounced was the concern of the WBC looking to subsidize the cost that comes with the Clean Boxing Program. Even with sponsorship, the sanctioning body is still coming out-of-pocket for a reported $75,000 per year on tests.
A question that wasn’t answered—neither in the seven weeks since Wilder (40-0, 39KOs) and Fury (27-0, 19KOs) publicly revealed their plans to collide later this year, nor in the four months since Fury first re-entered the WBC’s Top 15 heavyweight rankings—was when the unbeaten former heavyweight titlist from England would enroll in the program.
At least until they were finally cornered on the subject.
“Fury must enroll,” Mauricio Sulaiman, WBC president told BoxingInsider.com, through a statement from the WBC press office. “If he does not enroll, then the WBC cannot sanction the fight.”
Fury returned to the sport this past June, following a forced 31-month hiatus due to alcohol and drug abuse as well as mental health issues. The meltdown came on the heels of his career-best win, a 12-round landslide decision over Wladimir Klitschko in Nov. ’15 to win the lineal heavyweight championship, to which he still claims ownership.
The Irish Traveller never made a single defense, vacating one belt early when agreeing to a mandated rematch with Klithschko and then being stripped of all of his titles after the aforementioned sequel never came to pass. Fury twice postponed, first claiming an injury ahead of their planned July ’16 meet and then after getting popped by VADA for cocaine in his system during random testing ahead of their rescheduled fall ’16 battle.
Also in that period came an agreed-upon two year ban as issued by the United Kingdom Anti-Doping (UKAD), who claimed that Nandrolone was found in tests surrounding Fury’s win over Christian Hammer in Feb. ’15. The matter wasn’t discovered until later that year, but didn’t cause a delay in Fury’s title challenge versus Klitschko (other than Klitschko’s own four-week postponement due to an alleged injury sustained in training camp). Nor was the issue even readdressed until a hearing in June ’16, at which point UKAD charged Fury and his cousin, heavyweight contender Hughie Fury (who was popped for the same substance in March ’15) with presence of a prohibited substance.
Fury was finally cleared to fight in 2018, returning in June with a 4th round stoppage of Sefer Seferi. The victory was rewarded by the WBC with his being reinstated in their rankings, issued a #7 position in their heavyweight Top 15 pending his enrollment in their Clean Boxing Program. The organization has dropped several fighters for not agreeing to the program, but in the case of Fury merely kept moving the line in the sand.
Such concerns weren’t raised by any involved parties by the time he faced Francesco Pianeta this past August. Fury won a pedestrian 10-round decision, with the fight—largely forgettable on its own—overshadowed his post-fight in-ring “confrontation” with Wilder, who was ringside in Belfast to scout his then-potential future opponent.
The status went from potential to confirmed the moment Fury was declared the winner, as the two shared mostly playful insults during the on-air post-fight interview.
The fact that it has taken seven weeks (and counting) for event handlers to file the necessary paperwork with VADA contradicts claims made by Fury of his enrollment status.
Perhaps more revealing was his spray-painted verbal response, naming every drug testing organization that came to mind.
“I’m actually enrolled in VADA and USADA,” Fury told a group of reporters during the Los Angeles leg of his three-city press tour to promote the December 1, in video filmed by BoxingInsider.com’s own Jeandra LeBeauf. “They have to know my whereabouts. I have to tell World Anti-Doping (Agency) where I am within an hour every day.”
It also comes in stark contrast to Wilder’s longtime demands for his bouts to portray the image of a clean sport.
From the time he outpointed Bermane Stiverne to win the WBC strap in Jan. ’15, Wilder has been a vocal advocate for stricter drug testing protocol. Each of his seven title defenses have come with random testing existing far beyond the limited means in which most commission tests are conducted.
The unbeaten heavyweight from Alabama became something of a drug-testing jinx, with three of his scheduled challengers all busted by VADA for evidence of banned substances in their respective systems. Most notable among the lot was 2004 Olympic Gold medalist and former secondary titlist Alexander Povetkin coming up dirty for trace amounts of Meldonium, which ultimately killed their planned May ’16 title defense in Moscow, Russia.
Wilder would settle for a voluntary title defense, beating Chris Arreola that July in Birmingham, Alabama, less than an hour from his Tuscaloosa hometown. He’d return there for a Feb. ’17 title defense against Gerald Washington, who was brought in as a replacement for Andrzej Warwzyk, who was popped by VADA mere days after the fight was formally announced.
The one opponent who was caught but would get a second chance was Luis Ortiz, who attributed banned diuretics found in his system last September to prescription blood pressure medication. The then-unbeaten southpaw from Miami by way of Cuba was eventually cleared, but forced to sit out of their planned clash last November as punishment for failing to disclose the medication when he first filed paperwork with VADA.
Ortiz would get his chance this past March, pushing Wilder to the brink before eventually succumbing in the 10th round of their title fight thriller.
From there, Wilder has done his best to bring to light a clash with divisional rival and unbeaten, unified heavyweight titlist Anthony Joshua. Once it became clear that such a fight wouldn’t materialize in 2018—or if ever at all, the 6’7” heavyweight sought the next biggest event, which led to his team securing a deal with Fury.
What’s still left to do, is secure drug testing to ensure the biggest stateside heavyweight title fight this decade is, in fact, a clean event. Wilder continues to do his part, but that hardly covers all the bases.
“Mr. Wilder continues to be enrolled in the CBP,” Goodman confirmed to BoxingInsider.com, but with a kicker. “As yet, VADA has not been contacted by representatives of Mr. Wilder or Mr. Fury or by the WBC to test both fighters leading up to their December bout.”
With less than eight weeks to go before the opening bell, the clock is ticking for such testing to even serve its full purpose.
When Will Deontay Wilder Step Up?
When Will Deontay Wilder Step Up
By: Matthew N. Becher
It has been two years now that Deontay Wilder (37-0 36KO) took on Bermane Stiverne in Las Vegas and became the WBC Heavyweight champion, winning a unanimous decision. Since then wilder has defended his title four times, against Eric Molina, Johann Duhaupas, Artur Szpilka and Chris Arreola. Out of those four fights, three have been in his home state of Alabama. Also, out of those four fights, zero have been against any major competition. Wilder has a fight scheduled in two weeks against former USC football player Gerald Washington, at the Legacy Arena in, you guessed it, Birmingham Alabama. The question that arises is when Wilder will actually decide to fight some legit competition, to either unify the titles or to just give fans a more evenly matched fight.
In the coming months, the Heavyweight division will be ripe with decent match ups where belts will exchange hands, and or new kings will be crowned. Joseph Parker will defend his newly minted WBO title against the Lineal champions (Tyson Fury), Cousin Hughie Fury, in New Zealand. It may not be a top of the line matchup, but it is none the less a very good fight that keeps the division rolling toward ultimate unification. Also, the best heavyweight of the past decade will see if he has one last run in him, when 40 year old Wladamir Klitschko will take on Anthony Joshua in front of 90 thousand screaming fans at Wembley Stadium in April. So while the likes of a young lion, Joshua , are breaking attendance records in the UKs most famous venue, Wilder will be fighting, yet again, in a small arena in Alabama (one that he will also, most likely, not sell out)
Recently, undefeated Cuban Heavyweight, Luis Ortiz, has called out Wilder on social media.
“Tell Deontay Wilder stop running, I’m Here: I’m ready to fight you on February 25th!” said Ortiz, who is now, currently ranked as the #2 Heavyweight in the WBC Rankings. Wilder responding to Ortiz’s offer of fighting him by saying he would never fight someone that has previously failed a drug test.
Something that Ortiz did do, in 2014. Since then, Ortiz has been tested 12 times, all coming back clean, and was enrolled in the VADA testing program since last September. It now looks like Ortiz will take on former WBC champ, Stiverne, to become the #1 contender.
It just seems that “The Bronze Bomber” Wilder is content with holding on to his one title and milk his championship run in the easiest manner possible. Taking fights against unranked fighters that are also under the PBC banner. Also staying away from prominent fight locations like Las Vegas, or even just not fighting in his own home state may show why he is keeping himself safe, locked away inside his own personal bubble. We would love to see what the young American champ can do when he is really tested against another quality opponent, but for now, we will have to watch him fight former college football players, who couldn’t make it to the pros.